Inclusion and exclusion criteria
pulmonary mycosis, pneumonia, PTB, dyspnea, fever, expectoration, Pulmonary Mycosis, chest pain, tuberculosis, pulmonary fungal infection, cough, rales or pleural friction, hemoptysis
PULMONARY MYCOSIS, PNEUMONIA, INFILTRATION, DISEASE, INVASIVE PULMONARY ASPERGILLOSIS, LUNG INFECTION, TUBERCULOSIS, INFECTIONS, CAVITY
Case group: Eligible patients included those with confirmed PTB and pulmonary fungal infection who simultaneously meet the diagnostic criteria for tuberculosis according to the “Health Industry Standards of the People's Republic of China” issued in 2017 [Control group: Eligible patients included those with confirmed PTB but without pulmonary fungal infection who only meet the diagnostic criteria for tuberculosis according to the “Health Industry Standards of the People's Republic of China” issued in 2017 [Following are the diagnostic criteria for pulmonary fungal infection according to the “Expert Consensus on the Diagnosis and Treatment of Pulmonary Mycosis” proposed by the Infections Group of the Respiratory Society of the Chinese Medical Association in 2007: 1. at least present one host incidence risk factor. 2. Those who meet clinical characteristics of pulmonary mycosis {(1) Main clinical features: 1. invasive pulmonary aspergillosis with chest X-ray and Computed Tomography examination showing increased subpleural nodules or halo symptoms around the lesions in the early stages of the disease; chest X-ray and CT examination showing pulmonary cavity or a crescent sign 10–15 days after onset; 2. Pneumocyte pneumonia: chest CT examination showing hair glass lung interstitial infiltration. (2) Secondary clinical features: 1. continuous fever > 96 h with no significant improvement after aggressive antibiotic treatment; 2. symptoms and signs of a lung infection, including cough, expectoration, hemoptysis, chest pain, dyspnea, moist rales or pleural friction sound; 3. imaging examination showing new non-specific lung infiltration other than the main clinical features}, 3. Those presenting lung histopathological evidence. 4. Those with microbiological evidence {(1) direct microscopy of the endotracheal attractor or qualified sputum samples showing hyphae, and the same fungus is isolated two consecutive times in the culture. (2) BALF is detected by direct microscopy with a positive fungal culture. (3) Qualified sputum or BALF direct microscopy or culture showing 